Table 3.

Daptomycin treatment success in Staphylococcus aureus bacteremia, stratified by methicillin susceptibility (MSSA versus MRSA) and therapies used^a

Therapy	No. of cases with successful daptomycin response/total no. of cases (%)	P value	No. of MSSA cases with successful daptomycin response/total no. of MSSA cases (%)	P value	No. of MRSA cases with successful daptomycin response/total no. of MRSA cases (%)	P value
Daptomycin at initial dose of:
>6 mg/kg	50/60 (83)	0.408	15/17 (88)	0.315	35/43 (81)	0.722
<6 mg/kg	15/20 (75)		5/7 (71)		10/13 (77)
Concomitant β-lactam
With β-lactam	26/30 (87)	0.336	8/8 (100)	0.121	18/22 (82)	0.825
Without β-lactam	39/50 (78)		12/16 (75)		27/34 (79)
Concomitant rifampin
With rifampin	13/17 (76)	0.569	1/2 (50)	0.186	12/15 (80)	0.968
Without rifampin	52/63 (83)		19/22 (86)		33/41 (80)
Concomitant gentamicin
With gentamicin	6/8 (75)	0.633	1/2 (50)	0.186	5/6 (83)	0.846
Without gentamicin	59/72 (82)		19/22 (86)		40/50 (80)
Concomitant vancomycin
With vancomycin	7/9 (78)	0.777	3/4 (75)	0.624	4/5 (80)	0.983
Without vancomycin	58/71 (82)		17/20 (85)		41/51 (80)

^aSome patients received more than one concomitant therapy. Data are not shown for concomitant linezolid (n = 2, both MRSA, with 1 failure and 1 success) and concomitant trimethoprim-sulfamethoxazole (n = 2, both MRSA, with 1 failure and 1 success).